MORAb-202, an Antibody Drug Conjugate Utilizing Humanized Anti-Human FRa Farletuzumab and the Microtubule-Targeting Agent Eribulin, Has Potent Anti-Tumor Activity
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-17-1215
Full Text
Open PDFAbstract
Available in full text
Date
September 27, 2018
Authors
Publisher
American Association for Cancer Research (AACR)